NCT04281498 2025-02-04
Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
Icahn School of Medicine at Mount Sinai
Heinrich-Heine University, Duesseldorf